Skip to main content

Advertisement

SpringerLink
Log in

Arsenic trioxide transarterial chemoembolization with and without additional intravenous administration of arsenic trioxide in unresectable hepatocellular carcinoma with lung metastasis: a single-blind, randomized trial

  • Original Article - Clinical Oncology
  • Published:
Journal of Cancer Research and Clinical Oncology Aims and scope Submit manuscript

Abstract

Aim

To evaluate the efficacy and safety of arsenic trioxide transarterial chemoembolization and intravenous administration in unresectable hepatocellular carcinoma with lung metastasis.

Methods

A single-blind, two-parallel group, randomized trial was conducted at three medical centers (Guangzhou, China), including patients with both biopsy-confirmed hepatocellular carcinoma and lung metastasis. The experimental group received arsenic trioxide transarterial chemoembolization and intravenous administration of arsenic trioxide, while the control group only received arsenic trioxide transarterial chemoembolization. We compared overall survival (OS), time to progression (TTP), disease control rate (DCR), and objective response rate (ORR) between the groups.

Results

Between April 2013 and June 2014, 139 patients received the allocated intervention, 70 of whom were in the experimental group and 69 of whom were in the control group. No patient was lost to follow-up. The median OS was 7.3 (95 % CI = 6.8–7.8) months in the experimental group and 2.9 (95 % CI = 2.6–3.1) months in the control group (P < 0.001). The median TTP was 2.7 (95 % CI = 1.9–3.3) months in the experimental group and 1.2 (95 % CI = 1.0–1.9) months in the control group (P = 0.023). In the experimental group, the DCR was 72.85 % and the ORR was 7.14 %, while in the control group, the DCR was 7.24 % and the ORR was 0.00 %. DCR and ORR differed significantly between the two groups (P < 0.001 and P = 0.024, respectively).

Conclusions

Arsenic trioxide transarterial chemoembolization and intravenous administration were safe and effective in unresectable hepatocellular carcinoma with lung metastasis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

Abbreviations

HCC:

Hepatocellular carcinoma

TACE:

Transarterial chemoembolization

BCLC:

Barcelona Clinic Liver Cancer

OS:

Overall survival

TTP:

Time to progression

DCR:

Disease control rate

ORR:

Objective response rate

As2O3 :

Arsenic trioxide

CI:

Confidence interval

CT:

Computed tomography

RECIST:

Response Evaluation Criteria In Solid Tumors

CR:

Complete response

PR:

Partial response

SD:

Stable disease

PD:

Progressive disease

References

  • Baj G, Arnulfo A, Deaglio S, Mallone R, Vigone A, De Cesaris MG, Surico N, Malavasi F, Ferrero E (2002) Arsenic trioxide and breast cancer: analysis of the apoptotic, differentiative and immunomodulatory effects. Breast Cancer Res Treat 1:71–73

    Google Scholar 

  • Cabrera R, Nelson DR (2010) Review article: the management of hepatocellular carcinoma. Aliment Pharmacol Ther 31(4):461–476

    Article  CAS  PubMed  Google Scholar 

  • Chen GQ, Shi XG, Tang W et al (1997) Use of arsenic trioxide (arsenic trioxide) in the treatment of acute promyelocytic leukemia (APL): I. Arsenic Trioxide exerts dose-dependent dual effects on APL cells. Blood 89(9):3345–3353

    CAS  PubMed  Google Scholar 

  • Cheng AL, Kang YK, Chen Z et al (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10:25–34

    Article  CAS  PubMed  Google Scholar 

  • Eisenhauer EA et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228–247

    Article  CAS  PubMed  Google Scholar 

  • Ferenci P, Fried M, Labrecque D, Bruix J, Sherman M, Omata M, Heathcote J, Piratsivuth T, Kew M, Otegbayo JA et al (2010) Hepatocellular carcinoma (HCC): a global perspective. J Clin Gastroenterol 44:239–245

    Article  PubMed  Google Scholar 

  • Lin CC, Hsu C, Hsu CH, Hsu WL, Cheng AL, Yang CH (2007) Arsenic trioxide in patients with hepatocellular carcinoma: a phase II trial. Investig New Drugs 1:77–84

    Google Scholar 

  • Llovet JM, Ricci S, Mazzaferro V et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378–390

    Article  CAS  PubMed  Google Scholar 

  • Maeda H, Hori S, Nishitoh H et al (2001) Tumor growth inhibition by arsenic trioxide (arsenic trioxide) in the orthotopic metastasis model of androgen-independent prostate cancer. Cancer Res 61(14):5432–5440

    CAS  PubMed  Google Scholar 

  • Moon Y, Park G, Kim Y et al (2004) Arsenic trioxide (arsenic trioxide) sensitivity of carcinoma cell lines and cancer cells from patients with carcinomatosis peritonei. Ann Clin Lab Sci 34(3):271–276

    CAS  PubMed  Google Scholar 

  • Oketani M, Kohara K, Tuvdendorj D et al (2001) Inhibition by arsenic trioxide of human hepatoma cell growth. Cancer Lett 183:147–153

    Article  Google Scholar 

  • Parkin DM, Bray F, Ferlay J, Pisani P (2000) Estimating the world cancer burden: globocan. Int J Cancer 94(2001):153–156

    Google Scholar 

  • Qian J (2011) Interventional therapies of unresectable liver metastases. J Cancer Res Clin Oncol 137(12):1763–1772

    Article  PubMed  Google Scholar 

  • Shindoh J et al (2013) Risk factors of post-operative recurrence and adequate surgical approach to improve long-term outcomes of hepatocellular carcinoma. HPB (Oxford) 15(1):31–39

    Article  Google Scholar 

  • Vuky J, Yu R, Schwartz L, Motzer RJ (2002) Phase II trial of arsenic trioxide in patients with metastatic renal cell carcinoma. Investig New Drugs 20(3):327–330

    Article  CAS  Google Scholar 

  • Wu XZ, Xie GR (2008) Induced differentiation of hepatocellular carcinoma by natural products. Afr J Tradit Complement Altern Med 5(4):325–331

    PubMed Central  CAS  PubMed  Google Scholar 

  • Yu J, Qian H, Li Y et al (2007) Therapeutic effect of arsenic trioxide (arsenic trioxide) on cervical cancer in vitro and in vivo through apoptosis induction. Cancer Biol Ther 6(4):580–586

    Article  CAS  PubMed  Google Scholar 

  • Zhang P, Zhao Y (2010) Tumor biology and tumor load on effects of prognosis of colorectal cancer liver metastases liver resection treatment. J Hepatobiliary Surg 3:234

    Google Scholar 

Download references

Acknowledgments

This study was funded by the Science and Technology Foundation of Guangdong Province, China (Grant No. 2011A030400009) and the Natural Science Foundation of Guangdong Province, China (Grant No. S2012010010569).

Conflict of interest

There are no conflicts of interest to declare.

Author information

Authors and Affiliations

  1. Department of Interventional Radiology, Cancer Center, Guangdong Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China

    Bing Liu, Jian-wen Huang, Yong Li, Bao-shan Hu, Xu He, Wei Zhao, You-bing Zheng & Li-gong Lu

Authors
  1. Bing Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jian-wen Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yong Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Bao-shan Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Xu He
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Wei Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. You-bing Zheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Li-gong Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Li-gong Lu.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Liu, B., Huang, Jw., Li, Y. et al. Arsenic trioxide transarterial chemoembolization with and without additional intravenous administration of arsenic trioxide in unresectable hepatocellular carcinoma with lung metastasis: a single-blind, randomized trial. J Cancer Res Clin Oncol 141, 1103–1108 (2015). https://doi.org/10.1007/s00432-014-1866-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00432-014-1866-1

Keywords

Search

Navigation